Akeso Advances Dual-Antibody Cancer Trial, Keeping Oncology Pipeline in Focus

Akeso, Inc. (HK:9926) announced an update on their ongoing clinical study.

The study, titled “An Open-label, Multicenter, Phase Ib/II Study to Evaluate the Safety, Tolerability and Antitumor Activity of AK119 in Combination With AK112 in Patients With Advanced Solid Tumors,” aims to test a new drug combo in hard-to-treat cancers. It focuses on safety first, then early signs of how well the treatment may slow or shrink tumors.

The trial tests two antibody drugs from Akeso, Inc., AK119 and AK112, given by IV every three weeks. AK119 targets a pathway that may help tumors evade the immune system, while AK112 is designed to block blood vessel growth and boost immune attack at the same time.

This is an interventional study in Phase Ib/II, so it is still early stage but already looking beyond basic safety. All patients receive the same treatment in sequence, there is no placebo group, and both doctors and patients know what is given, which keeps the focus on quick readouts of safety and activity.

The study was first submitted on January 10, 2023, signaling when the program formally entered the clinical pipeline. The most recent update on March 16, 2026, confirms the trial is still active and recruiting, with key future dates for primary and final completion likely to guide later readouts and valuation shifts.

For investors, this update reinforces Akeso’s push to build a broader oncology portfolio around multi-target antibody drugs. A smooth safety profile and early tumor responses could support sentiment toward 9926, especially against global immuno-oncology peers, while any safety flags or weak data could cap near-term upside.

The study remains ongoing with recent updates posted, and further details are available on the ClinicalTrials portal.

To learn more about HK:9926’s potential, visit the Akeso, Inc. drug pipeline page.